Erythropoiesis is a complex multistep process encompassing the differentiation of hemopoietic stem cells to mature erythrocytes. The steps involved in this complex differentiation process are numerous and involve first the differentiation to early erythoid progenitors (burst-forming units-erythroid, BFU-E), then to late erythroid progenitors (colony-forming unitserythroid) and finally to morphologically recognizable erythroid precursors. A key event of late stages of erythropoiesis is nuclear condensation, followed by extrusion of the nucleus to produce enucleated reticulocytes and finally mature erythrocytes. During the differentiation process, the cells became progressively sensitive to erythropoietin that controls both the survival and proliferation of erythroid cells.
Introduction

Basic background
The hematopoietic system in vertebrates requires the presence of cells that ensure a continuous production of new cells needed to replace mature blood elements endowed with only a limited lifespan. This continual blood cell production is ensured by pluripotent stem cells, which have the unique property of both self-renewal and differentiation through progressive commitment to multipotent progenitors, then to committed progenitors and finally to progressively maturing precursors.
In mouse (and also in humans) during embryonic/fetal development, three distinct stages of erythropoiesis have been defined. The first stage corresponds to primitive embryonic erythropoiesis and occurs at the level of blood islands that develop within the yolk sac around day 7 of murine embryonic life; the distinctive feature of erythropoiesis at this stage corresponds to the Epo-independency. 1 Primitive erythroblasts differentiate within the bloodstream, remain predominantly nucleated at the end of their maturation and have a very large size (accordingly, they are called 'megaloblasts'). The second stage of erythropoietic development corresponds to definitive erythropoiesis and occurs around day 10 of gestation and consists of a rapid and marked proliferation of erythroid elements in the fetal liver. The third stage of erythropoietic development is characterized by the migration of hematopoietic stem cells at the level of the bone marrow, where adult hemopoiesis and, particularly, adult erythropoiesis develops.
Erythropoiesis involves the progressive differentiation starting from hemopoietic stem cells to mature erythrocytes. The steps involved in this complex differentiation process are numerous and involve first the differentiation to multipotent hemopoietic progenitors generating mixed colonies in vitro (CFU-Mix), and then to committed erythroid progenitors subdivided in early erythroid progenitors (burst-forming uniterythroid, BFU-E) generating in vitro large erythroid colonies and late erythroid progenitors (colony-forming unit-erythroid, CFU-E) generating small erythroid colonies and finally to morphologically recognizable erythroid precursors. During this differentiation process, the cells became progressively sensitive to erythropoietin due to the appearance of the erythropoietin receptors on these cells.
The compartment of bone marrow erythroid precursors is well characterized and involves a proliferative-maturative compartment, involving maturation from proerythroblasts to polychromatophilic erythroblasts through the basophilic stage, and a maturative nonproliferative compartment involving maturation from polychromatophilic erythroblasts to mature red blood cells through the reticulocyte stage. The end cells, erythrocytes, are uniform biconcave disks lacking a nucleus and organelles and composed in large part by a highly specialized protein, hemoglobin. The bone marrow erythropoiesis is a highly efficient system that tunes the rate of erythropoietic production to physiologic needs. In this system, the physiologic stimulus is hypoxia representing the signal inducing the synthesis of erythropoietin (Epo), the main cytokine involved in the control of erythroid production. In spite of the efficiency of the erythropoietic system, a small, but significant level of inefficient erythropoiesis due to premature intramedullary death of erythroid cells occurs. Recent studies indicate that this inefficient erythropoiesis is due to the apoptotic death of erythroblasts.
The main biochemical and molecular events occurring during the process of erythroid differentiation and maturation are briefly outlined in Figure 1 . BFU-E progenitors take about 14 days to differentiate in vitro forming large colonies; CFU-E progenitors take about 7 days to form colonies in vitro. CFU-E progenitors undergo 3-5 mitotic divisions to differentiate to terminal erythrois elements through different maturation steps: proerythroblasts, basophilic erythroblasts, polychromatophilic erythroblasts and orthochromatic erythroblasts. Finally, these cells undergo terminal maturation by extruding their nuclei and progressively losing all organelles: as a consequence of these processes, young erythrocytes, called reticulocytes, are formed. As erythroid precursors progress in their maturation, they undergo a progressive decrease in their size, an increase in hemoglobin concentration and an increase in chromatin density.
This review will show the relevance of apoptotic mechanisms in the control of erythropoiesis under physiologic and pathologic conditions.
Role of the Epo EpoR in the control of erythropoiesis
Several decades of studies have shown that Epo represents the main cytokine involved in the control of erythropoiesis. Red blood cell production is strictly dependent on the interaction of Epo with its single transmembrane receptor (EpoR). Epo is secreted from the kidney and fetal liver according to a molecular mechanism triggered by hypoxia. The main targets of Epo are represented by bone marrow erythroid cells expressing EpoR: particularly, late erythroid progenitors (CFU-E) and proerythroblasts, where the EpoR is maximally expressed (about 1000 receptors per cell).
The crucial role of Epo and its receptor for red blood cell production is directly supported by knockout studies in mice of the Epo and EpoR: Epo À/À and EpoR À/À mice die at day 12.5 of embryonic life as a consequence of severe anemia. Epo À/À or EpoR À/À mice exhibited a normal number of erythroid progenitors (BFU-E and CFU-E) at the level of the fetal liver, thus showing that Epo and its receptor are not required for the commitment of hemopoietic stem cell to the erythroid lineage. 1 The interaction of Epo with EpoR homodimer determines a conformational change of the EpoR subunits, with consequent activation of the signal transduction machinery.
The signal transduction pathways induced by the activated EpoR are complex and have been elucidated only in part. As a class I cytokine receptor, EpoR initiates Epo-dependent signal transduction through the activation of the Janus kinase (JAK2), which binds the EpoR at the level of a conserved structure called Box1 motif (reviewed in Wojchowski et al 2 ). Through JAK2 activation, EpoR induces multiple signalling pathways, which acting together orchestrate the complex cell machinery involved to prevent apoptosis and to support terminal erythroid proliferation and differentiation. Among them, the phosphatidylinositol 3 kinase (PI3K), AKT kinase and Ras signalling pathways play a key role in the mediation of many biological actions induced by Epo.
Another important pathway activated by EpoR is represented by Stat5, a member of the Stat family, acting downstream numerous cytokine receptors and regulating cell growth survival and differentiation via activation of target genes acting as a transcription factor. Given the potential role of Stat5 in the induction and modulation of antiapoptotic mechanisms elicited by Epo, the role of this peculiar transcription factor in erythropoiesis will be analyzed in detail below.
In addition to Epo and its receptor, other cytokines play an important role in the control of erythropoiesis. In this context, particularly relevant is the role of the stem cell factor (SCF), also known as the kit ligand (KL) and its receptor (SCF-R or c-kit). ckit is expressed in the majority of CD34 þ hemopoietic progenitors and its expression is maintained at high levels during the stages of differentiation from BFU-E to CFU-E; at later stages of differentiation during the maturation of CFU-E, c-kit expression progressively declines and disappears in polychromatophilic and orthochromatic erythroblasts. 3 These findings imply that SCF may exert effects on erythroid cells during early and late stages of erythroid differentiation and may act also on immature erythroid precursors. 3 
Figure 1
Outline of the process of erythroid differentiation. In the top panel, the main features of the erythroid cell morphology are schematically represented. In the other three panels, the kinetics of expression of several molecules during erythroid differentiation is shown. These molecules are divided, according to their function, into three main groups represented by transcription factors, growth factor receptors and proteins important for erythroid cell structure and/or function.
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These observations clearly showed that c-kit signalling is indispensable for normal erythropoiesis. On the other hand, numerous in vitro and in vivo experiments have shown that KL and Epo coadministration results in a stimulation of erythropoiesis and BFU-E and CFU-E colony stimulation: particularly, the in vitro administration of KL together with Epo resulted in a marked enhancement of erythroid proliferation, associated with a delay in erythroid maturation.
In addition to Epo and SCF, glucocorticoids also have a remarkable effect on erythropoiesis. These hormones act through nuclear receptors, and recent investigations indicate that mice deficient in glucocorticoid receptor expression exhibit a complete loss of stress erythropoiesis, that is, the capacity to respond with an increased erythropoietic production to stress conditions, such as erythrolysis or hypoxia. 4 
Molecular mechanisms of control of erythropoiesis: role of transcription factors
The process of erythropoietic differentiation, as well as the whole process of hemopoietic differentiation, is orchestrated at the molecular level by a complex network of transcription factors that act by regulating the expression of a set of target genes.
Among these different transcription factors, GATA-1 seems to play a key role in erythroid development. This zinc-finger transcription factor, expressed in erythroid and megakaryocytic cells, binds to GATA-binding motifs present in the promoters and/or enhancers of all erythroid-specific genes (reviewed in Cantor and Orkin 5 ). GATA-1 is scarcely expressed in quiescent erythroid progenitors, but is rapidly induced when these cells are induced to erythroid differentiation by Epo and then progressively accumulates during erythroid maturation, being abundantly expressed during all stages of erythroid maturation. 6, 7 The highest levels of GATA-1 are observed in CFU-Es and proerythroblasts. 8 The hemopoietic phenotype of GATA-1 knockout mice showed severe anemia with the production of an erythroid progeny, resulting in a maturational arrest at the level of proerythroblasts. Studies on GATA-1 À/À embryonic stem cells induced in vitro to erythroid maturation showed that these cells failed to mature beyond the proerythroblast stage and undergo rapid apoptosis, thus suggesting an essential role for GATA-1 in erythroid survival, in addition to erythroid maturation. 9 According to these observations, it seemed logical to assume that one or more GATA-1 target genes, which normally exert their physiological function at the proerythroblast/basophilic erythroblast stages, are strictly necessary for the survival and terminal maturation of erythroid precursors. However, surprisingly, an examination of the expression of several important potential target genes showed that they continued to be expressed at approximately normal levels in the absence of GATA-1. 10 Among these potential target genes, one could be represented by Bcl-X L , an antiapoptotic protein whose expression is strongly induced by GATA-1.
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In addition to binding DNA, other transcription factors exert their activity through protein-protein interactions. A prototype of this category of factors is represented by FOG-1 (Friend of GATA-1), a zinc-finger transcription factor that binds to the amino zinc-finger of GATA-1 (reviewed in Cantor and Orkin 5 ). FOG-1, abundantly expressed in erythroid and megakaryocytic cells, is coexpressed with GATA-1 during erythroid development and plays a key role in the control of erythropoiesis: in fact, FOG-1 mice die of severe anemia caused by an erythroid maturation block similar to that observed in GATA-1 À/À mice.
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Erythroid differentiation is also influenced by other transcription factors acting either at early or late stages of the differentiation process. An important role in the control of early stages of erythropoiesis is played by Tal-1, a member of the basic helix-loop-helix (bHLH) family of transcription factors. Tal-1 expression is essential for the early development of the primitive and definitive hematopoietic systems. Tal-1 expression is strictly required for proper erythroid and megakaryocytic differentiation (ie, in the absence of tal-1, no erythroid and megakaryocytic differentiation is observed). 13 Like other tissuerestricted bHLH transcription factors, Tal-1 binds DNA as a heterodimer with the ubiquitously expressed E proteins, which recognizes the hexanucleotide sequence CANNTG found in a wide variety of eucaryotic transcriptional enhancers, particularly at the level of erythroid and megakaryocytic genes. In normal adult tissues, Tal-1 expression is restricted to hematopoietic and endothelial cells and, particularly in erythroid cells, Tal-1 is initially expressed at low levels in quiescent erythroid progenitors, but becames highly expressed throughout the entire differentiative and maturative process and forms active heterodimers with E2A, participating in the activation of erythroidspecific genes.
14 In fact, antisense oligomers to Tal-1 inhibit proliferation and self-renewal of erythroleukemia cells, 15 and forced Tal-1 expression exerts a stimulatory effect on erythroid development of normal hemopoietic progenitors. 16 It is of interest to note that several studies suggest that the capacity of Tal-1 to influence the hemopoietic differentiation depends more on the capacity to form transcriptional complexes with other transcription factors than on its DNA-binding properties. This intriguing conclusion is directly supported by the observation that Tal-1 mutants that lack a DNA-binding domain are able to rescue primitive erythropoiesis from in vitro differentiated Tal-1 À/À embryonic stem cells.
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Antiapoptotic mechanisms operating in erythroid cells
Stat5
The signal transducer and activator of transcription (Stat) proteins have a dual role as signal transducers and activators of transcription. These proteins are latent in the cytoplasm and are activated by extracellular signalling cytokines or growth factors that bind to specific cell surface receptors.
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Stat 5 is a transcription factor present in the cytoplasm in a latent form and activated by the EpoR, as well as many other cytokine receptors. As a consequence of EpoR activation, Stat5 binds to phosphorylated tyrosines present on the cytoplasmic tail of the EpoR, and itself becomes phosphorylated at the level of tyrosine residues. The activated Stat5 dimerizes and is translocated from the cytoplasm to the nucleus, where it modulates the expression of several genes involved in the control of cell proliferation and differentiation. In addition to these genes, Stat5 activates the expression of several antiapoptotic genes in erythroid cells, most notably Bcl-X L , through a direct binding at the level of Stat5-binding consensus sequences present in the promoter of the Bcl-X L gene. [19] [20] [21] [22] These effects of Stat5 on Bcl-X L activation may represent the molecular basis to explain the antiapoptotic effects elicited by Stat5 in erythroid cell lines, 19 while dominant-negative Stat5 induces a growth arrest and apoptosis of erythroid precursors. 23 Studies on mice that lack the expression of both Stat5a and Statb isoforms supported the protective role of Stat5 in erythroid cell survival. Stat5a
À/À /Stat5b À/À mice embryos are severely anemic as a consequence of an impaired survival of liver erythroid progenitors. Particularly, fetal liver cells derived from Stat5a À/À Stat5b À/À animals generated a low number of erythroid colonies in vitro, showed a three-fold increase in the frequency of apoptotic cells and a pronounced increase in the percentage of apoptotic cells when grown in vitro in the presence of Epo. 19 In spite of marked anemia during embryonic life, Stat5a
Stat5b
À/À mice exhibited a moderate condition of anemia at birth, which was progressively attenuated in animals of adult age (at adult age only about 50% of Stat5a À/À Stat5b À/À mice were anemic). However, the adult Stat5a À/À Stat5b À/À mice, in spite of their near-normal hematocrit levels, are deficient in generating high erythropoietic responses following a stress stimulation (ie, the induction of a chemically induced haemolytic anemia). 24 The analysis of erythropoiesis in Stat5a
showed the existence of an increased pool of immature erythroblasts exhibiting reduced Bcl-X L levels and undergoing apoptosis at a high rate with respect to the corresponding cells of wt animals. 24 In conclusion, the analysis of Stat5 knockout mice strongly suggests that the antiapoptotic effect of this transcription factor in erythroid cells is exerted at the level of immature erythroid cells and is mediated mainly via modulation of Bcl-X L . In line with this observation, Stat5a and Stat5b and Bcl-X L exhibit a similar pattern of expression during normal erythroid maturation, with a progressive increase of expression during the differentiation from BFU-E to CFU-E and to immature erythroid precursors, followed by a rapid and marked decline at later stages of maturation (polychromatophilic and orthochromatic erythroblasts). (Figure 2 ).
It is of interest to note that Stat5a5b deficiency also induces a premature death of myeloid precursors, which seems to be related to a decrease of Bcl-2 and Bcl-X L . 25 Role of Bcl-X L as an antiapoptotic factor in erythropoiesis Bcl-X L pertains to the family of Bcl-2-related proteins that act as important regulators of cell death, integrating competing apoptotic and antiapoptotic signals to modulate the activation of the cell death machinery. The Bcl-2 family members can be classified into three different groups on the basis of comparative analysis of their structure-function: (i) 'multidomain' death antagonists (Bcl-2, Bcl-X L , Bcl-w, Mcl-1 and A1); 'multidomain' death agonists (Bax, Box and Bok); and (iii) 'BH3-only' proapoptotic proteins (Bim, Bid, Bik and Bak). The first two groups of Bcl-2 members function to protect or disrupt the integrity of mitochondrial membranes, respectively, while BH3-only proteins trigger cell death through binding to the receptor domain of multidomain Bcl-2 members, thereby mediating the inactivation of the antiapoptotic members or the activation of the proapoptotic members. 26, 27 Bcl-X L as well as Bcl-2 are supposed to be inserted into the outer mitochondrial membrane through a hydrophobic C-terminal motif. The main function of the antiapoptotic Bcl-2 family members seems to consist of promoting adaptation and maintaining the vitality of mitochondria to various types of perturbations of cellular metabolism. 28 Particularly, the antiapoptotic mechanism of Bcl-X L , as well as of other Bcl-2 family members, seems to be related to the inhibition of the activity of Bid and Bax, which cooperate in the formation of pores in the membrane of mitochondria, allowing the release of components of these organelles in the cytoplasm, with a subsequent loss of their function. 29 Recent studies, however, suggest a broader role of Bcl-2 in the control of apoptosis, which cannot be limited to the control of mitochondrial membrane integrity and also consists of a general control of caspase activation program independent of the cytochrome c/ Apaf-1/caspase-9 apoptosome. 30 Therefore, two models have been proposed to explain the antiapoptotic activity of Bcl-2/Bcl-X L . In the first model, BH3-only proteins can directly bind and activate Bak/Bax, and this phenomenon may be inhibited by Bcl-2/Bcl-X L -mediated sequestration of BH3-only proteins. In the second model, the binding of BH3-only proteins to their primary targets Bcl-2/Bcl-X L leads to a neutralization of these antiapoptotic factors, resulting in the activation of Bax/Bak. 31 Gene targeting studies of antiapoptotic Bcl-2 family members provided clear evidence that they exhibit a unique physiologic role, nonredundant with the activity of other cell death inhibitors, indicating that each Bcl-2 protein is essential for the survival of some cell types: thus, Bcl-2 is required for the survival of kidney, melanocyte stem cells and mature lymphocytes; Bcl-X L for neuronal and erythroid cells; Bcl-w for sperm progenitors; A1 for neutrophils and Mcl1 for zygote implantation (reviewed in Cory and Adams 31 ). Particularly interesting were the phenotypic features observed in the Bcl-X gene knockout: in fact, Bcl-X À/À mice die at E13, exhibiting massive cell death at the level of neuronal elements of the central nervous system and of erythroid elements present in the fetal liver. 32 
Figure 2
Kinetics of Stat5A and Sta5B expression in The level of action of Bcl-X L in the protection of erythroid cells from apoptosis was investigated in detail using mouse embryonic stem cells in which both alleles of the Bcl-X L gene were disrupted. 33 The introduction of Bcl-X L À/À embryonic stem cells into mouse blastocysts clearly showed that these cells were unable to contribute to the generation of definitive erythroid cells. 33 Bcl-X L À/À embryonic stem cells generated in vitro a number of erythroid colonies similar to those originating from wt embryonic stem cells; however, a significant proportion of erythroid precursors present in the erythroid colonies of Bcl-X L À/À cells undergo apoptosis during their maturation. 33 These findings strongly suggested that Bcl-X L is a critical antiapoptotic regulator of erythropoiesis. The role of Bcl-X L in adult erythropoiesis was explored through the study of transgenic mice conditionally deficient in Bcl-X L gene. 34 At 3 months of age, these animals exhibited a condition of severe hemolytic anemia, associated with platelet deficiency. 34 The analysis of the bone marrow of these animals showed a hyperplasia of both megakaryocytic and erythroid precursors; the rate of apoptosis in erythroid precursors of Bcl-X L -deficient animals was only slightly increased as compared to that observed for the corresponding cells of normal animals. Since these animals suffered from a condition of severe anemia and had increased numbers of reticulocytes, it was concluded that Bcl-X L is essential for the survival of red blood cells. 34 Studies on an immortal line of phenotypically normal mouse erythroblasts provided further details about the antiapoptotic role of Bcl-X L in erythroid maturation. 35 These cells were maintained in an undifferentiated state by agents promoting selfrenewal, such as SCF and glucocorticoids, while they were induced to differentiate by Epo. Overexpression of the Bcl-X L gene allowed these cells to undergo terminal differentiation to mature erythrocytes in the absence of Epo. 35 The molecular basis responsible for the elevated expression of Bcl-X L in erythroid cells is unknown at the moment. The promoter of the Bcl-X L gene used for the start of the transcription in erythroid cells is localized at 5 0 in close proximity to the start initiation codon ATG. 36 This promoter region contains several putative regulatory regions recognized by some transcription factors, including GATA-1, NF-E2 and Ets-1 and other transcription factors pertaining to the Ets family 36 This promoter region contains a Stat-binding element, able to bind Stat-5. 37 GATA-1 plays an important positive role in the regulation of Bcl-X gene expression. 38 Particularly, it was shown through the analysis on conditional knockout models that the expression of GATA-1 in embryonic stem cells strongly induces BCL-X L , but not Bcl-2, expression in erythroid cells and this may represent one of the mechanisms responsible for the antiapoptotic effects exerted by GATA-1 in erythroid cells. 38 Finally, more recent studies have led to the identification of the major start site of Bcl-X L gene transcription in erythroid cells. This site corresponds in the human Bcl-X gene at À654, relative to the ATG initiation codon; furthermore, an enhancer element was identified at position À1804 through À1734.
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Epo deprivation induces the activation of caspase-3, leading to apoptosis of erythroblasts. 40 Since activated caspase-3 was reported to cleave Bcl-X L , 41 it is conceivable that Epo protects erythroid cells from apoptosis in part via blockage of caspase-3-dependent cleavage of the Bcl-X L protein. Furthermore, it was shown that the activation of ERK1 and ERK2 by Epo upregulates Bcl-X L expression via inhibition of caspase activities, thus resulting in the protection of erythroid cells from apoptosis. 42 Few studies have explored the expression of Bcl-X L , as well as of Bcl-2, in hemopoietic progenitors (ie, in total CD34 þ cells or in fractions of CD34
þ cells, such as 34
Studies on human CD34 þ cells have shown that both Bcl-X L and Bcl-2 are widely expressed in these cells; in contrast, in CD34 þ /38 À cells (corresponding to early, immature hemopoietic progenitors), Bcl-X L is preferentially expressed as compared to Bcl-2. 43, 44 The kinetics of Bcl-X L expression during erythroid differentiation and maturation was explored using different cellular models of erythroid differentiation. Using human CD34 þ cells grown either in erythroid (SCF þ Epo) or in granulocytic (SCF þ G-CSF) cell culture medium, it was shown that at days 4 and 8 of culture, Bcl-X L expression was markedly more pronounced in erythroid than in granulocytic precursors. 45 In a second cellular system, an immortalized murine cell line was used: these cells correspond to immature murine erythroid precursors isolated from p53 À/À mice that proliferate in medium containing SCF and Dexamethasone, while they differentiate in medium containing Epo and Insulin. 46 When shifted to a differentiating medium, these cells undergo terminal maturation in 72 h. Bcl-X L expression in these cells progressively increases, reaching maximal expression at terminal erythroid maturation. 46 In another study, immature murine erythroblasts, mainly corresponding to proerythroblasts, have been isolated from the spleen of mice infected 2 weeks earlier with an anemia-inducing strain of Friend virus and then induced in vitro to terminal erythroid maturation in the presence of Epo; alternatively, cells corresponding to CFU-E have been isolated after 1 week of culture in vitro of BFU-E in semisolid medium and then grown in vitro in the presence of Epo up to terminal maturation. In both these cell culture systems, Bcl-X L was expressed at very low levels in immature erythroblasts and its expression progressively and markedly increased during maturation up to terminal erythroblasts. 47 We have reinvestigated Bcl-X L expression in erythroid cells using a unique unilineage cell differentiation system involving the selective differentiation of purified peripheral blood CD34 þ cells to erythroid cells in liquid suspension in serum-free medium in the presence of very low concentrations of interleukin-3 (0.01 U/ml) and GM-CSF (0.001 ng/ml) and in the presence of saturating amounts of Epo (3 U/ml). This culture system allows exploration of the differentiation of BFU-E to CFU-E (from day 0 to days 5-6 of culture) and the maturation of CFU-E to mature erythroblasts and to reticulocytes (from day 7 to days 14-15 of culture). In parallel, using different unilineage cell culture systems allowing the selective differentiation of CD34 þ cells to granulocytic or monocytic or megakaryocytic cells, we have compared the pattern of Bcl-X L expression observed in other hematopoietic cell lineages. In quiescent CD34
þ cells, we observed a low Bcl-X L expression ( Figure 3) . A marked increase in Bcl-X L expression was observed during early stages of the differentiation of CD34 þ to the erythroid lineage (day 4 and day 7, when the cells correspond to a stage intermediate from a BFU-E to a CFU-E and to CFU-Es/proerythroblasts, respectively); Bcl-X L levels continued to increase during the early and intermediate stages of erythroid maturation, reaching a peak level of expression when the majority of erythroid cells had reached the stage of polychromatophilic erythroblasts; during terminal stages of erythroid maturation (days 14-16 of culture), a marked decline in Bcl-X L expression was observed ( Figure 3 ). The administration of SCF to the erythroid cultures moderately potentiated Bcl-X L expression, associated with terminal erythroid maturation ( Figure 3 ). In contrast, Bcl-2 expression was limited only to the early stages of erythroid differentiation and completely declined to very low or undetectable levels during the maturation of erythroid cells.
The study, in parallel, of Bcl-X L expression in other hemopoietic lineages showed that this antiapoptotic protein exhibits in the Mk cells, a pattern of expression similar to that observed in erythroid cells; in contrast, in granulocytic cells, Bcl-X L was expressed at low levels only during initial stages of differentiation and thereafter declined to virtually undetectable levels ( Figure 3 ). In contrast, Bcl-2 was detectable at low levels only during the initial stages of Mk differentiation and then declined to low or undetectable levels; in contrast, in granulocytic cells, Bcl-2 was expressed at sustained levels during all stages of differentiation and maturation ( Figure 3 ).
Recent studies have suggested that in erythroid cells, Bcl-X L could exert other biologic functions in addition to its role as an antiapoptotic factor. In fact, studies performed on the Friend erythroleukemia cell line showed that the inhibition of Bcl-X L expression (by antisense transcripts) in these cells elicited a marked inhibition of hemoglobin synthesis after DMSO induction, as well as an increased rate of apoptosis. 48 Importantly, this inhibitory effect of Bcl-X L deficiency on hemoglobin synthesis was also observed in cells overexpressing Bcl-2. 48 The inhibitory effect on hemoglobin synthesis caused by Bcl-X L deficiency was due to an inhibition of heme synthesis and not to a reduction of globin mRNA expression. 48 Furthermore, studies of enforced expression i.v. of the FDCP-Mix multipotent progenitor cell line have indicated a novel role for Bcl-X L in cell fate decision beyond cell survival. 49 In fact, the erythroid expression of Bcl-X L in these cells was associated with an induction of erythroid differentiation and prohibited the generation of myeloid cells. 49 Abnormalities in Bcl-X L expression and/or function have been involved in the pathogenesis of some disorders of the erythroid lineage. In this context, the observations made in polycythemia vera are particularly relevant. Polycythemia vera (PV) is an acquired myeloproliferative disease characterized by the accumulation of morphologically normal red cells, white cells and platelets. 50 Since the accumulation of red cells dominates the clinical picture, the disease was called polycythemia. In spite of several decades of biochemical studies, the mechanisms responsible for the accumulation of erythrocytes in this disease remain unknown. However, some physiopathological mechanisms relevant for the development of the disease have been identified and they indicate that PV erythroid cells are resistant to some apoptotic stimuli. 51 In line with this finding, it was shown that erythroid cells obtained from the bone marrow of patients with PV exhibit increased levels of Bcl-X L as compared to those observed in normal erythroblasts. 52 Bcl-X L overexpression may explain the accelerated differentiation of PV erythroid progenitors in vitro in the absence of Epo, in contrast to normal erythroblasts, as well as their survival advantage in vivo, where Epo production is very low.
It is of interest to note that recent studies have indicated that Bcl-X L may represent a major target of some antitumor chemotherapeutic drugs. Therefore, Bcl-X L levels may represent a major determinant in the protection of the erythroblasts from apoptotic cell death induced by DNA-damaging chemotherapeutic drugs.
In spite of their structural heterogeneity and their different molecular targets, many chemotherapeutic agents kill tumor cells by inducing apoptosis. The majority of these drugs mediate cell death through activation of the intrinsic apoptosis pathway ( Figure 4) ; this pathway is activated by different types of intracellular stresses, such as genetic damage or growth factor deprivation, and implicates the Apaf-1-dependent activation of caspase-9, following the release of cytochrome c and Smac/ Diablo from mitochondria. 53 This pathway is regulated by the proapoptotic multidomain and BH3-only Bcl-2 proteins and their antiapoptotic counterparts, which also includes Bcl-X L . In addition to representing one of the main molecules involved in the cell protection in the intrinsic apoptotic pathway, Bcl-X L may represent also a direct target of some chemotherapeutic drugs. In fact, it was shown that Bcl-X L can be modified by deamidation of asparagines residues, at the level of an unstructured loop separating the a1helix-BH4 domain and the a2helix-BH3 domain. 54 Bcl-X L deamidation was observed in tumor cells or in mouse embryonic fibroblasts p53 À/À treated with different types of genotoxic agents, including cisplatin, etoposide, taxol and g-irradiation. 54 The deamidation of Bcl-X L has as a consequence led to its inactivation, with a consequent loss of Bcl-X L binding to Bim and subsequent induction of apoptosis. The same authors also showed that the hypopho- Apoptotic mechanisms in the control of erythropoiesis U Testa sphorylated active form of retinoblastoma protein (Rb) inhibits deamidation of Bcl-X L , suppressing through this mechanism the apoptosis induced by DNA-damaging agents.
Anemia is a common complication of cancer, often resulting in a decrease in the quality of life and influencing the outcomes of patient care. The myelosuppressive effects of chemotherapy are a major cause of anemia in cancer patients. Chemotherapyinduced anemia is a result of two different mechanisms acting at the level of: (a) the bone marrow progenitor/stem cell compartment and (b) the immature erythoid precursors (proerythroblasts and basophilic erythroblasts). 55 The latter mechanism was recently clarified, showing that immature normal erythroblasts are extremely sensitive to the cytotoxic effect of chemotherapeutic agents, such as cisplatin, etoposide or campothecin, while mature erythroblasts (acidophilic erythroblasts) are almost completely resistant. 55 Importantly, Epo also at high doses was unable to protect immature erythroblasts from chemotherapyinduced apoptosis. According to these observations, it was concluded that the primary target of chemotherapy-induced apoptosis is represented by proerythroblasts and basophilic erythroblasts. 55 Interestingly, preincubation of erythroid cells with SCF resulted in a marked protection of immature erythroid cells from chemotherapy-induced apoptosis. 55 The mechanism of this protection seems to be related to an SCF-mediated upregulation of Bcl-2 and Bcl-X L expression, associated with a consequent inhibition of caspase activation. 55 At the moment, it is unknown whether the inhibition of chemotherapic-induced apoptosis could be related to an inhibition of Bcl-X L deamidation, possibly mediated by upregulation of hypophosphorylated Rb expression.
Hydroxyurea, another myelosuppressive agent, also elicited apoptosis of erythroid cells through a mechanism involving a strong upmodulation of the TRAIL receptor 2. 56 
Role of cell death receptors in the control of erythropoiesis
Ligands and cell death receptors pertain to the tumor necrosis factor (TNF) and TNF receptor (TNF-R) superfamilies, respectively. Members of the TNF family of membrane-bound and secreted ligands pair off with one or more specific cell surface receptors that form a corresponding family of cognate receptors (TNF-Rs). Each ligand-receptor pair is considered a system, and actually more than 40 distinct ligand-receptor systems are currently recognized. 57 Members of both the TNF ligand and TNF-R superfamilies exhibit several remarkable structural similarities. 58 The TNF ligands are type II transmembrane proteins, characterized by an extracellular C terminus domain, named the 'TNF homology domain': this domain contains a conserved framework of aromatic and hydrophobic residues, responsible for the association of single molecules to form a trimer. 59 Most of the TNF ligands are synthesized as membranebound proteins, but soluble forms may be generated by a process of limited proteolysis. The solubilization of some ligands is associated with a considerable loss of biological activity: this is the case of the Fas ligand (Fas L) and of the TNF-related apoptosis-inducing ligand (TRAIL). The main molecules pertaining to the TNF ligand superfamily are represented by TNF-a, FasL, TRAIL, TWEAK, RANKL, APRIL and Lymphotoxin-a (LTa). Signal transduction through the intrinsic apoptotic pathway. The intrinsic apoptotic pathway is initiated by different stimuli mainly represented by growth factor deprivation or genotoxic agents such as antitumor chemiotherapics or g-irradiation. The initial events are represented by the activation of 'BH3-only' proteins such as Bid and Bim; these activated proteins are subsequently translocated to the mitochondrial membrane, where they associate with and inactivate the antiapoptotic proteins Bcl-2 and Bcl-X L . The proapoptotic proteins, Bax and Bad, are activated and generate in the mitochondrial membrane a protein-permeable conduit, with consequent release of cytochrome c and other mitochondrial proteins. The release of cytochrome c induces the formation of apoptosome in association with Apaf1 and caspase-9. The Apoptosis-inducing factor (AIF) released by mitochondria is capable of inducing apoptosis independent of caspases. Smac/DIABLO released from the mitochondria interacts with and inactivates the 'Inhibitor of apoptosis' (IAP) with the consequent activation of caspases.
More than 40 TNF-Rs have been identified. The majority of them are type I transmembrane proteins, with an extracellular domain N terminus and with an intracellular domain C terminus; a notable exception is represented by the TRAIL-R3, which is anchored to the cell membrane through a covalently linked C-terminal glycolipid. 58 Many of these receptors possess a stretch of amino acids, the death domain (DD), as part of their sequence. 59 The DDs are required for apoptotic signalling. For some of these receptors, soluble forms may be generated through a process of limited proteolysis (TNF-R1 and TNF-R2) or of alternative splicing (Fas).
Each member of the TNF ligand superfamily binds at least one receptor of the TNF-R superfamily: FasL binds selectively to Fas; TRAIL may bind to four different membrane receptors, called TRAIL-R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4; and TNF-a binds two membrane receptors, TNF-R1 and TNF-R2. The majority of the TNF-R superfamily members function as membrane receptors transducing a signal following interaction with their ligands. These signalling receptors may be subdivided into two groups on the basis of the structure and function of their cytoplasmic region: one of the two receptor groups possesses a DD that mediates the association between the receptor and a death adaptor protein; the other group does not possess this death cytoplasmic domain. The TNF-Rs, TRAIL-R1 and TRAIL-R2, as well as Fas, are typical examples of death receptors. Two examples of DD adaptors are represented by FADD (also known as MORT1) and TRADD: FADD possesses two interfaces: one interacting with the DD of Fas and the other one interacting with intracellular effector enzymes (caspases that initiate the apoptotic process). 60 The other adaptor called TRADD (TNFRassociated death domain) can initiate apoptosis through FADD or may stimulate protein kinases involved in the control of phosphorylation cascades to induce the transcription of some immune-system modulation genes. TRADD seems to be involved in the apoptotic signalling of the TNF-R, but not of Fas and TRAIL-Rs. 61 Some of the receptors of the TNF receptor superfamily are decoy receptors able to compete with signalling receptors for ligand binding, thereby, inhibiting their function. Examples of decoy receptors are given by DcR1 and DcR2 (also known as TRAIL-R3 and TRAIL-R4), competing with TRAIL-R1 and TRAIL-R2, respectively, for binding of TRAIL and DcR3 (sFas) competing with Fas for binding of FasL. 60 The physiologic role of these receptors is still unclear, but it has been suggested that they could protect some normal cells from their cytotoxic ligands.
The series of biochemical events elicited by the interaction of a death ligand with its receptor has in part been elucidated and can be summarized briefly as follows ( Figure 5 ). The engagement of death receptors by their ligands activates the extrinsic apoptotic pathway. This pathway leads, as the intrinsic apoptotic pathway, to the activation of caspases independent of p53. The activation of a death receptor by its ligand leads to the recruitment at the level of the receptor of a death adaptor, which in turn determines the rapid assembly of a death-inducing signalling complex (abbreviated as DISC), with consequent activation of the apoptosis initiating caspase-8 and -10.
Caspase-10 is an initiator caspase found in primates but not in rodents. The role of this caspase in initiating the apoptotic process is supported by two observations: (a) lymphocytes from ALPS II patients bearing caspase-10 mutation are resistant to TRAIL-mediated killing and 62 (b) endogenous caspase-10 is activated and recruited at the level of the DISC and is capable of transmitting an apoptotic signal in the absence of caspase-8. 63 In fact, caspase-8 and -10 directly cleave the 'executione' caspase-3. Activated caspase-8 and -10 are also able to activate by proteolytic cleavage Bid, which is responsible for the activation of the proapoptotic arm of the Bcl-2 gene superfamily, with the consequent release of apoptogenic factors from mitochondria. Particularly, SMAC/DIABLO released from mitochondria promotes apoptosis through its capacity to bind and neutralize the inhibitor of apoptosis proteins (IAP), thus preventing the activity of these factors as attenuators of the caspase activation.
Recently, evidence was accumulated showing that death receptors and their ligands may act as negative regulators of erythropoiesis, and that their action may play a physiologically relevant role in the control of the rate of erythropoiesis. Furthermore, abnormalities of these receptors may play an important role in the physiopathology of some anemic conditions, as will be discussed later. Evidences are now analyzed showing the effect elicited by the activation of the main death receptors on normal erythropoiesis.
Effect of TNF-a on normal erythropoiesis: The binding of TNF-a to the TNF-R1 leads to a cascade of events, outlined above, that determines the induction of apoptosis, as well as NFkB activation and JNK activation. Given the signal transduction pathways activated by this cytokine, it is not surprising that TNFa is able to induce a variety of biological effects. Mouse TNF and TNF-R1 gene knockout studies have clearly shown that this cytokine plays a key role in protection against infection by bacterial, fungal and parasitic pathogens.
In initial studies carried out in vivo 64, 65 and in vitro, 66 evidence was provided that TNF-a exerted an inhibitory effect on erythropoiesis. In addition, in a phase I study of TNF-a in cancer patients, a clear decrease in hemoglobin levels after 1 month of TNF-a treatment was observed. Subsequent in vitro studies, however, showed that the inhibitory effect of TNF-a on erythropoiesis at the CFU-E level was likely mediated by IFN-b released by macrophages in response to TNF-a and not due to a direct effect of TNF-a on erythroid progenitors. 67, 68 However, in another study, a direct effect of TNF-a on erythroid progenitors (BFU-E) was suggested, mediated by the TNF-R1. 69 A direct effect of TNF-a on erythroid cells was supported by subsequent studies. Using preparations of virtually pure erythroid precursors derived from unilineage erythroid cultures, it was shown that TNF-a exerts a moderate, but significant, inhibitory effect on the proliferation of immature erythroblasts (proerythroblasts and basophilic erythroblasts), associated with a slight induction of apoptosis, in the presence of erythropoietin. Furthermore, TNF-a, like other death receptor ligands, exerted an inhibitory effect on erythroid maturation. 70 A direct effect of TNF-a on erythroid cells was also supported by a recent study showing that: (i) both murine and human CFU-E release TNF-a; (ii) the addition of neutralizing anti TNF-a antibody to cultures of human CD34 þ cells stimulated with Epo increased the generation of erythroid cells; (iii) the number of BFU-E colonies was higher in the bone marrow of TNF-a À/À mice than in wt mice; and (iv) the addition of TNF-a to TNF-a À/À mice elicited a significant inhibition of BFU-E colony formation, while TNF-a exerted only a slight inhibitory effect on wt mice BFU-Es. 71 An inhibitory effect of TNF-a on the generation of erythroid cells from purified human CD34 þ cells was also reported in another recent study. 72 In this study, it was also shown that a detectable expression of TNF-R1 was observed only during the initial stages of erythroid differentiation, while TNF-R2 expression was observed during all stages of erythroid differentiation. 72 However, it is unlikely that the inhibitory effects of TNF-a on erythropoiesis could be mediated via TNF-R2 signalling, in that this receptor lacks a death domain in its cytoplasmic tail.
The inhibitory effect of TNF-a on erythroid maturation seems to involve NF-kB induction. 72 In fact, NF-kB activity is high in early erythroid progenitors and then declines at later stages of erythroid maturation. In fact, low NF-kB levels are required for the induction of the expression of erythroid-specific genes. 73 Effects of the Fas-FasL pathway on normal adult erythropoiesis: Without death by apoptosis, the life of cells of the immune system and their precise function would not be Signal transduction through the extrinsic apoptotic pathway. Engagement of the either TNF or TRAIL or FasL with their cognate receptors TNF-R1 or TRAIL-R1 or -R2 or Fas results in the formation of a receptor proximal complex containing the adaptor proteins TRADD and FADD. These adaptor proteins in turn recruit additional key pathway-specific enzymes, such as caspase-8, and they became activated and initiate downstream events leading to apoptosis.
Apoptotic mechanisms in the control of erythropoiesis U Testa possible: lymphocyte homeostasis is mainly mediated by the Fas/FasL pathway. 74 Growing evidence indicates that the Fas/FasL system could also play a relevant role in the regulation of hematopoiesis and, particularly, of erythropoiesis.
Initial studies on mice with mutations of either the Fas or FasL system failed to show significant modifications of the hematopoiesis. However, a re-evaluation of the hematopoiesis in Fas or FasL-deficient mice showed a striking extramedullary increase in hematopoietic progenitors, including both erythroid and nonerythroid progenitors; furthermore, CFU-S and CFU-C on peripheral blood and in spleen clearly increased in these mice after birth. 75 These observations clearly indicate that the Fas/ FasL system can affect hematopoiesis during both the fetal and adult life. These conclusions were supported by the observation showing that mice with mutations of the Fas (lpr mice) or of the FasL gene (gld mice) show a pronounced increase in the number of CFU-GM. 76 The expression of Fas/FasL during erythroid differentiation has been explored in detail. Initially, it showed low Fas mRNA expression in CD34 þ cells isolated from human bone marrow. 77, 78 Immature primitive hematopoietic progenitors (CD34 þ /38 À ) from human fetal liver express significant amounts of Fas antigen, whereas the more mature progenitors (CD34 þ /38 þ ) showed low Fas antigen expression. 79 Both TNFa and interferon-g (IFN-g) induced a marked increase in Fas expression on CD34 þ cells. 77, 79, 80 Interestingly, the expression of Fas antigen on CD34 þ cells was greatly increased following the induction of the cycling of these cells with cytokines, such as SCF, IL-3 and GM-CSF. 79 Other studies have explored the consequences of Fas activation in progenitor cells on the induction of apoptosis, proliferation and differentiation. Basically, these studies have provided evidence that immature progenitor cells are resistant to Fas-mediated apoptosis. Lin À /Sca þ /cKit þ stem cells reveal little or no constitutive expression of Fas and are resistant to the apoptotic triggering by an anti-Fas agonistic antibody. 81 However, if these stem cells are induced to cycle by incubation with early-acting growth factors and incubated in the presence of TNF-a, they exhibit a marked upmodulation of Fas antigen expression and became sensitive to Fas-mediated apoptotic triggering. 81 These findings are also confirmed by studies on human CD34 þ cells derived from either peripheral blood or cord blood: these cells are found to be resistant to the apoptotic triggering elicited by either soluble FasL or anti-Fas agonistic antibody. 82 However, if CD34 þ cells are induced to proliferate in the presence of flt3 ligand, SCF and thrombopoietin, they became sensitive to anti-Fas-mediated apoptosis. The resistance of quiescent CD34 þ cells to Fas-mediated apoptosis seems to be related to the expression in these cells of elevated levels of c-FLIP (FLICE-inhibitory protein), a dominant-negative inhibitor of caspase 8.
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Other studies have directly evaluated Fas/FasL expression in erythroid cells at various steps of differentiation and maturation. CFU-E constitutively express low levels of Fas, whose expression was potentiated by IFN-g; 83 interestingly, CFU-E-like cells possess low, but significant amounts of FasL, whose levels are potentiated by IFN-g treatment and by differentiation. 83 The expression of Fas and FasL was explored in detail by De Maria et al 84 using a selective system of unilineage culture of human erythroid cells starting from purified CD34
þ peripheral blood cells. Fas is clearly upregulated during the initial steps of erythroid differentiation from BFU-E to CFU-E, reaching elevated levels of expression at the stage of immature erythroblasts (proerythroblasts and basophilic erythroblasts) and the remaining expressed at significant levels up to terminal stages of erythroid maturation (orthochromatic erythroblasts). 84 These findings were also confirmed through the analysis of erythroid cells present in normal bone marrow. 84 Fas crosslinking was effective in inducing an apoptotic response only in immature erythroblasts, while mature erythroblasts are resistant to this triggering. 84 In contrast, an opposite pattern of FasL expression was observed, this membrane-bound ligand being expressed in late differentiating Fas-insensitive erythroblasts, mostly at the orthochromatic stage. FasL expressed on the membrane of mature erythroblasts was found to be functional in that it was able to kill Fas-sensitive lymphoblast targets in a Fasdependent manner. 84 Importantly, FasL-bearing mature erythroblasts displayed a Fas-mediated cytotoxicity against immature Fas-positive erythroblasts, which was in part abrogated by high concentrations of Epo. 84 According to these findings, it was suggested that erythropoiesis is regulated according to a negative feedback mediated by mature and immature erythroblasts, whereby the former cells might exert a cytotoxic Fasmediated effect on the latter cells within the erythroblastic island.
84 ( Figure 6 ). As mentioned above, Epo was able to partially protect immature erythroid cells from a strong triggering of the Fasmediated apoptosis, as it is induced by Fas agonistic antibodies. There is, however, evidence that other growth factors, like SCF, may exert a more pronounced protective effect than Epo. In this context, Lee et al 85 showed that anti-HLA-DR monoclonal antibody elicited a marked upregulation of Fas on primary human bone marrow cells, thereby increasing their susceptibility to Fas-mediated cell death. SCF partially antagonized Fasmediated apoptosis of primary cells, which suggests that SCF Figure 6 Negative regulation of erythropoiesis mediated by the interaction of FasL expressed on the membrane of mature erythroblasts with its receptor Fas present on the surface of immature erythroblasts. Following this interaction that takes place within the erythroblastic islands, the cells undergo either a maturation block/delay if the Epo concentration is high or an apoptotic process if the Epo concentration is low.
Apoptotic mechanisms in the control of erythropoiesis U Testa protects hemopoietic precursor cells from Fas-mediated apoptosis. 85 SCF may protect CFU-E from Fas-induced apoptosis: the protective effect of SCF was significantly more effective than the effect elicited by Epo. 86 This protective effect of SCF involves the activation of Src-kinases. 86 The simultaneous addition of IFN-g and FasL to CFU-E elicited a marked activation of caspase-8 and -3 with a consequent apoptotic response; this phenomenon was greatly inhibited by SCF addition, via a mechanism involving the upregulation of c-FLIP expression. 87 In another set of studies, the mechanisms through which Fasmediated apoptosis exert a negative control on erythropoiesis were explored in detail. These experiments take advantage of the observation that Fas triggering in the presence of high Epo concentrations elicited a low apoptotic response in immature erythroblasts, but induced a blockade of erythroid maturation. 70 This last mechanism requires caspase activation. 70 One of the major effects of caspase activation consisted in the degradation of the transcription factor GATA-1; the induction of GATA-1 degradation seems responsible for the Fas-mediated blockade of erythroid cell maturation since the transduction in erythroid progenitors of a caspase-resistant GATA-1 mutant resulted in a complete protection against Fas-mediated blockade of erythroid maturation. 70 Interestingly, the erythropoiesis blockade elicited by Epo deprivation was in part inhibited by the transduction of caspase-resistant GATA-1 in erythroid progenitors. 70 In a second study, it was shown that another transcription factor, Tal-1, is an additional target protein cleaved by activated caspases in erythroid cells. The transduction in hemopoietic progenitors of a Tal-1 mutant resistant to caspase cleavage protected erythroid cells from Fas-mediated inhibitory effect on erythroid maturation and cleavage of GATA-1. 88 Interestingly, the expression of the Tal-1 caspase-resistant mutant in erythroid cells completely protects these cells from the apoptosis elicited by erythropoietin deprivation. 88 The ensembling of these observations indicates that the apoptotic effects and the inhibitory actions on cell differentiation elicited by Epo deprivation or by death receptor triggering involve as a necessary step the caspase-mediated cleavage of two transcription factors, Tal-1 and GATA-1, whose integrity and activity are essential for erythroid maturation and survival ( Figure 7 ). 70 have shown that erythroid cells, in addition to Fas and TNF-R1, also express other death receptors, such as TRAIL-R1 and TRAIL-R2. The expression of these two membrane receptors was higher in immature than in mature erythroblasts. 70 TRAIL-R3 and TRAIL-R4 are not expressed at any stage of erythroid maturation. 89 Furthermore, it was shown that the membrane-bound form of the TRAIL was also expressed in normal erythroblasts, with a preferential expression at the level of mature erythroblasts. 70 Therefore, the pattern of TRAIL/TRAIL-R system in erythroid cells was highly comparable to that observed for the Fas/FasL system. Immature erythroid cells are sensitive to the antidifferentiative (in the presence of Epo) or cytotoxic (at low Epo concentrations) effects induced following the interaction of TRAIL with the TRAIL-Rs expressed on these cells. 70 These findings were confirmed in subsequent studies, showing that hemopoietic progenitors as well as mature erythroblasts are resistant to the apoptotic effects induced by TRAIL. 89, 90 The blockade of erythroid maturation induced by TRAIL-R triggering involves ERK1/2 activation, as suggested by the inhibition by pharmacological inhibitors of the ERK pathway. 89 The mechanism of TRAIL-induced apoptosis of erythroid cells was explored in experimental models of erythroid differentiation. Studies in erythroleukemia K562 cell line showed a sensitivity of these cells to TRAIL only after induction with hemin. 91 The induction of TRAIL sensitivity was not related to the stimulation of expression of TRAIL receptors, but to a downmodulation of c-FLIP. 91 
Effect of TRAIL on normal erythropoiesis: Initial studies performed by De Maria et al
Figure 7
Negative regulation of erythropoiesis triggered by death receptor activation or by erythropoietin deprivation: both these induce the apoptotic cascade, with the consequent activation of caspases that cleave the transcription factors GATA-1 and Tal-1. The cleavage of these transcription factors is responsible for either the maturation arrest or apoptosis of erythroid cells.
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Death receptors also influence the survival of other hemopoietic lineages: The activation of death receptors was also shown to affect the survival of other types of hemopoietic cells. In neutrophils, FasL, TRAIL and TNF interact with their respective receptors present on the membrane of neutrophils and per se do not induce apoptosis, but block the survival of these cells induced by growth factors, such as GM-CSF and G-CSF. 92 This inhibitory effect on growth factordependent survival seems to be mediated via the capacity of activated death receptors to bind in a caspase-independent manner tyrosine phosphatase SHP-1, which dephosphorylates JAK-2. 92 As a consequence of the binding of SHP-1, an inhibition of the growth factor receptor antiapoptotic signalling was observed; also, this last event was caspase independent. 92 This type of mechanism of action of activated death receptors was not explored in erythroid cells.
Animal studies indicating a role of death receptors in the control of erythropoiesis: Mice harboring targeted null mutations in Fas and TNFR-1 exhibit no significant defects in the erythroid lineage. However, studies performed in zebrafish have shown a very interesting observation. In fact, a hemopoieticspecific death receptor was identified in this animal species. 93 Very interestingly, the generation of transgenic mice expressing a dominant-negative inhibitor showed a specific phenotypic abnormality: the production of a surplus of erythroid cells. 93 At the moment, there is no evidence in mammals about a death receptor with a pattern of expression limited to the hemopoietic lineage. 93 
Induction of erythroid apoptosis by IFN-g: IFN-g is an
example of a cytokine that does not induce an apoptotic signalling per se, but may induce apoptosis of erythroid progenitors through an indirect mechanism involving upmodulation of both Fas and FasL, as mentioned above. In addition, IFN-g upmodulates the level of expression and activates several caspases, including caspase-8 and -3, in erythroid progenitors. 94 Paradoxically, IFN-g may exert a protective effect on apoptosis on erythroid cells at later stages of differentiation. 95 Ceramide, an intracellular second messenger produced by sphingommyelin hydrolysis, has been involved as a mediator of apoptosis induced by a number of cytokines, including IFN-g and TNF-a. Ceramide induces an inhibition of CFU-E colony formation. 96 Interestingly, the ceramide antagonist sphingosine-1-phosphate significantly reversed the CFU-E colony inhibition induced by IFN-g. 96 These observations suggest that ceramide is one of the key mediators of the inhibition of CFU-E colony formation by IFN-g. 96 
Role of caspases in erythroid maturation
There is evidence that these caspases may also display, in addition to a role in the apoptotic process, a function in the process of cell differentiation/maturation. Furthermore, some caspases are required for the process of normal erythroid differentiation.
The first evidences of a role for caspases in cell differentiation were derived from studies carried out in lens epithelial cells and in keratinocytes: caspase-3 is activated during terminal stages of lens epithelial cell differentiation; furthermore, caspase inhibitors block the denucleation of these cells occurring at the terminal stages of lens epithelial cell maturation. 97 Similarly, it was shown that caspases are activated during normal keratinocyte differentiation and this activation is required for the normal loss of the nucleus occurring at terminal stages of maturation. 97, 98 Recent studies have provided evidence that the 'spontaneous' activation of caspases was observed during later steps of cell maturation in various cell lineages, which include monocytic, megakaryocytic and erythroid lineages. During the process of normal maturation of monocytes to macrophages, an activation of caspase-3 and -9 was observed, associated with the release of cytochrome c from the mitochondria and cleavage of the protein acinus, but without induction of cell death. 99 The blockade of the caspase activity using synthetic cell-permeable inhibitors inhibited the cell maturation process. 99 Similar observations have been made in megakaryocytic cells. Caspase activation occurred at two stages of megakaryocytic maturation: (i) a first step of caspase activation (caspase-3 and -9 became spontaneously activated) occurred before proplatelet activation and was limited only to some cellular compartments and (ii) a second step of diffuse caspase activation occurred at the end of the maturation process after platelet release. 100 The first process of caspase activation did not lead to cell death, while the second wave of caspase activation was associated with cell death. 100 Importantly, the addition of caspase inhibitors to megakaryocytic cultures inhibited platelet release. In line with these observations, transgenic mice overexpressing the antiapoptotic gene Bcl-X L exhibited impaired platelet fragmentation. 101 Several lines of evidence indicate that caspase activation also occurs during the process of erythroid maturation and could play an important role in this process. In this context, an initial study showed that caspase-1, -2, -3, -5, -6, -7, -8 and -9 are expressed in erythroid cells. 102 The levels of procaspase-2, -3 and -8 were markedly higher in immature erythroblasts than in mature erythroblasts. 102 As expected, Epo deprivation elicited a marked increase in caspase activation. A transient caspase-3 and -7 activation was observed during the stages of erythroid maturation corresponding to proerythroblasts and basophilic erythroblasts; this phenomenon was transient in that the caspase activation regressed at later stages of erythroid maturation. 103 These caspases, transiently activated through the mitochondrial pathway, cleave proteins involved in nucleus integrity (lamin B) and chromatin condensation (acinus) without inducing cell death. 103 Inhibitors of caspases, such as z-VAD, added to erythroid cultures just before the moment of caspase activation elicited a block of erythroid maturation at the basophilic stage. 103 These findings have also been confirmed in murine erythroblasts. 104 Furthermore, it was shown that the overexpression of Raf-1, which prevents caspase activation, impairs erythroid maturation by reducing differentiation-associated caspase activation. 104 An opposite phenomenon was observed in Raf-1 À/À mice.
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A possible involvement of caspase in the control of erythroid cell production is also supported by the analysis of the phenotype of mice with the targeting of the genes encoding some of these caspases. In this context, the most interesting findings originated from the analysis of caspase-8 À/À mice. 105 Caspase-8 deficiency resulted in embryonic lethality, associated with two salient features: impaired heart muscle development and congested accumulation of erythrocytes. 105 These features resemble the phenotype reported also in mice with targeted disruption of FADD gene. 106, 107 The analysis of the defects in the erythroid lineage observed in these animals was, however, limited to the analysis of erythrocytes and it is, therefore, impossible to know whether mice with caspase-8 and FADD deficiency also exhibit abnormalities of erythroid cell maturation, in addition to an increased expansion of the number of mature erythrocytes. It is Apoptotic mechanisms in the control of erythropoiesis U Testa of interest that in a recently described family exhibiting a complete deficiency of caspase-8, no hemopoietic abnormalities have been described. 108 The discrepancy between the phenotype of caspase-8 deficiency in humans and mice could be related to the function in humans of caspase-10, the closest paralogue of caspase-8 in humans (caspase-10 has no known orthologue in mice).
In addition to caspases, recent studies also suggest a possible role of p53 during late stages of erythroblast maturation. Particularly, a high expression of the p53 protein was observed in late orthochromatic erythroblasts: this p53 activation may be related to the nuclear degradation occurring in these cells, without a fully executed apoptotic process. 109 
Apoptotic mechanisms in mature red blood cells
The occurrence of apoptotic processes and particularly of a possible activation of caspases was also explored in mature erythrocytes. These cells lack a nucleus and after a lifespan of about 120 days undergo a process of senescence and are then removed from the circulation. During this process, senescent erythrocytes undergo typical morphological changes, such as shrinkage as a consequence of the progressive release of microvescicles from the cell membrane and shape transformation from a discocyte to a spherocyte form, enabling first their recognition and then their phagocytosis by macrophages. In addition to these changes, there are a series of modifications at the level of the cell membrane, such as a progressive loss of the structural membrane protein spectrin and the loss of membrane asymmetry associated with the externalization of phosphatidylserine residues, resembling those observed in the process of apoptotic cell death in nucleated cells. These observations prompted studies aimed at evaluating whether mature RBCs possess an apoptotic machinery similar to that observed in the majority of nucleated cells. Human erythrocytes do not undergo programmed cell death when either treated with staurosporine and cycloheximide or when cultured in the absence of serum, conditions that induce apoptosis in all types of nucleated cells. 110 According to these observations, it was concluded that mature red blood cells do not have an apoptotic machinery and therefore do not undergo an apoptotic program. This issue was re-explored by the same authors on chicken erythrocytes, showing that serum deprivation or treatment with staurosporine and cycloheximide induces the death of these cells; however, although these erythrocyte deaths displayed many features that are typical of apoptotic cells, they are not blocked or inhibited by different types of caspase inhibitors. 111 According to these observations, it was concluded that chicken erythrocytes die without apparently activating caspases.
More recently, the problem was carefully re-evaluated in human erythrocytes. In this context, it was observed that mature erythrocytes contain considerable amounts of caspase-3 and caspase-8, while other main components of the apoptotic machinery such as caspase-9, Apaf-1 and cytochrome c are absent. 112 Although present at relatively high levels, caspase-3 and caspase-8 were not activable by various types of proapoptotic stimuli. 112 Recent studies suggest a possible role for caspase-3 in erythrocyte aging. 113 First, it was observed that activated caspase-3 can be detected in old, but not in young red blood cells; 114 second, this activated caspase-3 is able to cleave cell membrane band 3, disrupting its interaction with the peripheral membrane protein 4.2. 115 According to these observations, it was suggested that some caspases activated during red cell aging could participate in the degradation of crucial erythrocyte membrane proteins involved in the maintenance of shape and function. In line with these findings, it was observed that a loss of band 3 is associated with premature erythroid cell death (dyserythropoiesis). 116 Since an increase in Ca 2 þ concentration was associated with the aging of erythrocytes and was considered as one of the molecular mechanisms responsible for the senescence of these cells, additional studies have explored whether the induction of an increase of Ca 2 þ concentration in erythrocytes could trigger an apoptotic or apoptotic-like response. Following the induction of an increase of cytosolic Ca 2 þ concentration, erythrocytes undergo a rapid self-destruction process exhibiting several features of an apoptotic process, such as plasma membrane microvesciculation, phosphatidylserine externalization; this process culminates either in erythrocyte destruction or, in the presence of macrophages, in macrophage phagocytosis with subsequent destruction. 114 This process is inhibited by cysteine protease inhibitors, but not by caspase inhibitors. 114 Importantly, cysteine protease inhibitors allowed erythrocyte survival both in vitro and in vivo. 114 According to these findings, it was proposed that an increase in intracellular Ca 2 þ concentration in erythrocytes activates cysteine protease calpain that mediates spectrin cleavage and other morphological changes leading to cell shrinkage (Figure 8 ).
Role of deoxyribonuclease IIa in erythroid maturation
During the terminal stages of erythroid maturation, erythroblasts exhibit several features typical of an apoptotic process, such as a reduction of cell size, withdrawal from the cell cycle, nuclear condensation and nuclear expulsion. The progressive transition from the rapid proliferating compartment of immature erythroblasts to the terminal slowly proliferating compartment of mature erythroblasts is regulated by growth-inhibitory genes. 117 Many endonucleases have been implicated in the apoptotic process and particularly in DNA digestion occurring during apoptosis, such as caspase-activated DNase (CAD), deoxyribonuclease I (DNaseI) and deoxyribonuclease II (DNaseII). Two types of DNase II exist in mammalians that have been designated as DNase IIa and DNase IIb. DNase IIa is ubiquitously expressed, while DNase IIb is expressed only in the salivary gland.
Recent studies aimed at elucidating the physiological role of DNase IIa have shown a role of this enzyme in erythroid maturation and, particularly, in the process of enucleation occurring at very late stages of maturation. Mice deficient in DNase IIa expression were generated. These animals die of severe anemia and show a marked decrease of circulating red blood cells (ie, they have only 1/10 of the physiological number of circulating erythrocytes), associated with the presence in the circulation of definitive nucleated erythroblasts, a cell type normally present only in the bone marrow and not in peripheral blood. 118 The reduced presence of anucleated red blood cells in the peripheral blood of DNase IIa À/À mice cannot be related to a defect in erythroid commitment in that these animals exhibit a normal number of both BFU-E and CFU-E in their fetal liver. 118 However, mutant fetal liver erythroblasts showed a normal maturation after transfer into irradiated normal mice, thus suggesting that the defect of DNase II À/À erythroblasts is not intrinsic to these cells. In fact, histological experiments suggested that the source of DNase II responsible for the rescue of the maturation of DNase II À/À erythroblasts is represented by macrophages. In fact, it was suggested that central macrophages This conclusion was directly supported by the analysis of a second knockout of DNase IIa. In fact, the generated DNase II À/À mice die at birth, exhibiting at the level of the liver macrophages large DNA bodies resulting from the engulfment of undigested nuclei extruded from erythroblasts. 119 According to these findings, it was concluded that macrophages play an essential role in erythroid maturation through a biochemical mechanism involving DNase IIa.
The ensemble of these observations indicates that a regulated process of DNA fragmentation is strictly required for normal tissue homeostasis. 120 Furthermore, it is evident that the enucleation event occurring during late erythroid maturation is a regulated process requiring extensive signalling between erythroblasts and macrophages.
Role of AKT pathway in the apoptotic control of the erythroid lineage
In many cell types, the phosphoinoinositide-3-kinase (PI3K)/AKT (also known as protein kinase B) pathway plays a key role in the survival signalling in response to a variety of growth factors and this seems also to be the case in erythroid cells. The AKT/PKB pathway involves a cascade of activation/signalling steps that can be summarized as follows and that have been carefully reviewed in several recent papers: [121] [122] [123] [124] (a) the first step involves the activation and modulation of PI3K; PI3K may be activated through different mechanisms, involving either the binding of the complex p85/p110 (p85 is the regulatory subunit, while p110 is the catalytic Figure 8 Outline of the main apoptotic processes occurring during the process of erythroid differentiation. Mature erythroid cells exert a negative control on immature erythroblasts via FasL and other death receptor ligands. During the late stages of erythroid maturation, the activity of deoxyribonuclease II via macrophages is required for enucleation of orthochromatic erythroblasts with their consequent maturation to anucleated reticulocytes. During the senescence of red blood cells, an apoptotic-like process is observed, related to an increase in cellular Ca 2 þ concentration that leads to the activation of the proteolytic enzyme calpain with consequent plasma membrane micriveciculation, phosphatidylserine externalization and subsequent recognition, engulfment and destruction by macrophages.
Apoptotic mechanisms in the control of erythropoiesis U Testa subunit) to phosphorylated tyrosine residues present at the level of the cytoplasm domain of activated receptor tyrosine kinases or the interaction with members of the small GTPase family, such as Ras; (b) the second step consists in the generation of 3 0 -phosphorylated inositol lipids (PIP 3 ) that function as classical second messengers by binding proteins that harbor PIP 3 -binding domains; (c) PIP 3 binds the binding domain of the serine/threonine PKB/ AKT, with its consequent activation. (d) The activated PKB/AKT phosphorylates several components of the apoptotic machinery and through this mechanism induces antiapoptotic effects.
Particularly, PKB/AKT promotes cell survival by multiple mechanisms: (i) phosphorylation and inactivation of the proapoptotic protein Bad; (ii) maintenance of mitochondrial integrity; (iii) decrease of the expression of death genes, such as FasL and Bim, via the phosphorylation of forkhead transcription factor FKHR-L1: phosphorylated FKHR-L1 is exported from the nucleus to the cytoplasm where it is sequestered by 14-3-3 proteins; and (iv) increase of the transcription of survival genes through the activation of NF-kB and CREB transcription factors. [121] [122] [123] Furthermore, recent studies indicate that the PKB/AKT pathway is involved in the upregulation of survivin expression observed during cell cycle entry. 125 Survivin is a member of the IAP family that inhibits apoptosis by inactivating several caspases. 126 Initial studies on erythropoiesis and PKB/AKT signalling were based on the use of chemical inhibitors of PI3K. The PI3K inhibitor wortmannin blocked the PI3K activation elicited by Epo and considerably decreased the proliferation of erythroid precursors expanded in vitro. 127 Using a more specific and potent PI3K inhibitor (LY294002), an inhibitory effect on erythroid cell proliferation was confirmed, but it was also shown that PKB/AKT inhibition elicited the apoptotic death of a significant proportion of erythroid precursors. 128 In a subsequent study, the effects of the PI3K inhibitor LY294002 at earlier stages of erythroid differentiation have been explored, showing a marked inhibitory effect on the differentiation of CD34 þ to erythroid precursors: particularly, the addition of the inhibitor to CD34 þ cultures grown in the presence of Epo and SCF resulted in a marked inhibition of the generation of glycophorin-A þ cells. 129 The essential role of the PI3K in the mechanism of induction of erythroid proliferation and survival was also confirmed in a recent study. 130 It was also shown that three different mechanisms equally active in erythroid cells are responsible for PI3K activation: direct association of the PI3K to the EpoR; phosphorylation of Gab via either Tyr 343 or Tyr 401 of the EpoR; and phosphorylation of the IRS2 adaptor protein. 130 The activation of PKB/AKT following Epo stimulation requires a normal protein kinase C (PKC) activity, as suggested by the experiments carried out with PKC inhibitors. 131 As mentioned above, the FOXO family of Forkhead transcription factors is an important target of the activated PKB/AKT: activated PKB/AKT directly phosphorylates FKHR-L1 and other forkhead transcription factors resulting in cytoplasmic retention and inactivation, thus inhibiting the activity of these transcription factors required for the control of the expression of several genes involved in cell cycle control, cell death and oxidative stress. 132 There is evidence that the activation of FKHR-L1 alone can recapitulate all known elements of the apoptotic program normally induced by cytokine withdrawal. 133 FKHR-L1 is expressed in erythroid cells, its expression decreasing progressively during erythroid maturation. 134 In immature erythroid precursors, FKHR-L1 was rapidly phosphorylated by Epo through a PI3K-dependent pathway. 134 An additional target of PKB/AKT is represented by the glycogen synthetase kinase-3 (GSK 3), a serine/threonine kinase involved in metabolic processes (glycogen metabolism), andut also implicated in apoptosis regulation in primary human erythroid progenitors and its activity is suppressed by Epo, as well as by SCT. 135 Importantly, the inhibition of GSK3 using specific chemical inhibitors prevents apoptosis of erythroid progenitors by Epo deprivation. 135 The ensemble of these observations implicates at least two PKB/AKT targets, FKHR-L1 and GSK3, in the regulation of the survival of erythroid cells.
Other signalling pathways involved in the apoptotic regulation of erythroid cells
In addition to the PKB/AKT, other signalling pathways play a role in the survival of erythroid cells.
The transcription activator protein 1 (AP1) could play a role in the regulation of apoptosis mediated by Epo in erythroid cells. This is a transcriptional complex comprising members of the Jun and of the Fos families of transcription factors. Evidence was provided both in primary human hemopoietic progenitors and in Epo-dependent cell lines that both Epo addition or Epo deprivation induces AP-1 activity, and this AP-1 induction is required both for induction of erythroid proliferation and apoptosis. 136 The analysis of the composition of AP-1 transcriptional complex in these two conditions showed an interesting finding: JunB is present in erythroid cells, which triggered apoptosis by Epo deprivation, while c-Jun was present in erythroid cells induced to proliferate. 136 Finally, one of the two negative regulators of EpoR signalling, the small cytokine-inducible SH 2 -domain containing protein (CIS) plays a role in the control of erythroid cell apoptosis. 137 CIS belongs to the family of suppressor of cytokine signaling proteins and acts by reducing the Stat-5 activation elicited by Epo. The enforced expression of this protein in erythroid progenitors not only reduced their proliferation but also induced a significant level of apoptosis. 137 
Apoptotic mechanisms underlying pathologic conditions of erythropoiesis
The improvement of our understanding of the apoptotic mechanisms and their role in the control of erythropoiesis has prompted a series of studies focused in determining the abnormalities of these mechanisms occurring under some pathologic conditions involving the erythroid lineage. Usually, under pathologic conditions, an exacerbation of the apoptotic mechanisms is observed, leading to an increased destruction of erythroid precursors. These conditions are briefly analyzed here.
Apoptotic mechanisms underlying anemia occurring in rheumatoid arthritis
About 50% of patients with rheumatoid arthritis develop anemia of moderate entity, exhibiting all the laboratory features of an anemia associated with a chronic disease.
Recent studies suggest that the increased release of TNF-a could also be responsible for the development of anemia through the induction of an apoptotic mechanism. Studies performed in the bone marrow of anemic patients with chronic arthritis showed a significant decrease in the number of erythroid progenitors. 138, 139 The analysis of the erythroid compartment in these patients showed interesting findings: (i) a decreased number of mature erythroblasts; and (ii) an increased rate of apoptosis within the compartment of immature erythroblasts. 138 Interestingly, patients undergoing therapy with a blocking anti-TNF-a monoclonal antibody exhibit an improvement in anemia and in the proportion of apoptotic erythroblasts. 139 These observations may have potential implications in our understanding of the mechanisms underlying anemia not only in rheumatoid arthritis but also in other chronic inflammatory diseases.
Apoptotic mechanisms in the genesis of anemia in multiple myeloma
Anemia is a complication frequently observed in multiple myeloma, in that up to 70-80% of these patients exhibit a moderate to severe form of anemia (about 10% of these patients exhibit a severe form of anemia). A series of recent studies indicate that the anemia of multiple myeloma could be mediated through an apoptotic mechanism. Recent studies have showed FasL overexpression in multiple myeloma: 140 there is evidence that FasL expressed on tumor cells may mediate a tumor escape mechanism through elimination of the Fas þ effector lymphoid cells committed to tumor surveillance. The level of FasL expressed on myeloma cells usually correlates with the grade of malignancy: high-grade myeloma patients display higher levels of FasL on their membrane, compared with patients with a low-grade disease. 141 Similar observations have been made for TRAIL, whose expression was observed particularly in the tumor cells of patients exhibiting an aggressive disease. 141 Studies performed on myeloma patients at different stages of the disease have shown that in the bone marrow, there is an inverse relationship between the level of FasL expressed on myeloma plasmocytes and the hemoglobin level. 142 Furthermore, it was observed that in the bone marrow of patients with aggressive myeloma and high FasL levels, there is an increase of immature erythroblasts in the bone marrow, associated with a decrease of mature erythroid cells. 142 These observations argue in favor of the induction of apoptosis of erythroid cells mediated by the induction of FasL expressed on the surface of myeloma cells with Fas expressed on the membrane of immature erythroblasts. This hypothesis was supported by coculture experiments showing that myeloma cells are able to induce the cell death of erythroblasts, this phenomenon being inhibited by agents that block either Fas or FasL. 142 At the level of erythroid cells, the cell population more sensitive to apoptosis, mediated by myeloma plasmocytes, is represented by immature erythroblasts (ie, proerythroblasts and basophilic erythroblasts). Furthermore, immature erythroblasts from myeloma patients are more sensitive to FasL-mediated apoptosis than their normal counterparts. 142 Finally, apoptotic erythroblasts were observed in vivo in the bone marrow of myeloma patients; these cells showed a considerable expression of caspases-3 and -8 in both their proenzymatic forms and in cleaved, active subunits. 143 Erythroblasts isolated from the bone marrow of patients with aggressive myeloma displayed reduced levels of GATA-1, a transcription factor essential for erythroid cell survival.
According to these findings, it was proposed that the anemia observed in multiple myeloma may be related to two mechanisms: one dependent upon an elevated expression of FasL on the membrane of myeloma plasmocytes and the other dependent on an increased sensitivity of Fas þ immature erythroblasts to the apoptotic triggering elicited through the interaction of FasL þ plasmocytes with these cells; as a consequence of this interaction, there is the activation of the apoptotic machinery, activation of caspases and cleavage of GATA-1 with consequent arrest of cell maturation or induction of apoptotic cell death ( Figure 9 ).
Ineffective erythropoiesis and apoptosis in thalassemias
The unbalanced globin chain synthesis occurring in thalassemias leads to the formation of either free a-chains (b- Figure 9 Apoptotic mechanisms underlying the development of anemia in multiple myeloma patients. FasL and TRAIL highly expressed on the surface of malignant plasmocytes interact with their respective receptors present on the surface of immature erythroid cells with the consequent induction of the apoptosis of these cells.
Apoptotic mechanisms in the control of erythropoiesis U Testa thalassemias) or b-chains (a-thalassemias), which precipitate into the cytoplasm of erythroid precursors leading to the premature death of these cells and to hemolysis of mature red blood cells. 144 Under normal conditions, hemoglobin A (HbA) synthesis is coordinated to ensure a virtually equal synthesis of a-and b-globin chains and to minimize the accumulation of free subunits that form cytotoxic precipitates, resulting in premature cell death. Erythroid cells possess mechanisms to block a moderate imbalance in globin chain synthesis through the action of the alfa hemoglobin stabilizing protein (AHSP), an abundant erythroid-specific protein that is induced by GATA-1 and forms a stable complex with free a-globin chains. 145 This mechanism of protection of erythroid cells, however, is not sufficient to protect these cells when the globin chain synthesis is greatly unbalanced, as it occurs in thalassemias.
Erythrokinetics studies performed in b-thalassemia patients have provided clear evidence that the bone marrow is the main site of erythroid cell death: in fact, in these patients as many as 80% of the erythroid precursors die in the marrow. 146 The cause of the premature death of b-thalassemic erythroid precursors is due to apoptosis; in fact, the analysis of DNA laddering provided evidence that in b-thalassemia major, erythroid precursors, but not myeloid or lymphoid precursors, underwent an increased level of apoptosis. 147 Using flow cytometric techniques, it was shown that b-thalassemic erythroid precursors undergo apoptosis at a rate three to four times that of normal controls. 148 If the evaluation is carried out in absolute terms, it corresponds to an absolute increase in erythroid precursor apoptosis of about 15 times over the normal controls. 148 Analysis of the rate of apoptosis of erythroid precursors in different types of thalassemic patients, characterized by different levels of ineffective erythropoiesis, provided clear evidence that there is a direct correlation in these patients between the level of ineffective erythropoiesis and the percentage of apoptotic erythroblasts. 149 Hemopoietic progenitors have been purified from the bone marrow of b-thalassemic patients and induced in vitro to erythroid differentiation/maturation. Using this approach, it was clearly shown that erythroid cultures that originated from b-thalassemic patients exhibit a limited expansion, compared to control cultures, due to the death of erythroid cells when they reach the maturation stage corresponding to polychromatophilic/orthochromatic erythroblasts. 150 Particularly, in this study, a marked increase in the proportion of apoptotic polychromatophilic and orthochromatic erythroblasts was observed in bthalassemic cultures. 150 The occurrence of apoptosis at the polychromatophilic stage coincides with the stage where intensive hemoglobinization occurs and could be explained by the increase in a-globin production and precipitation.
In spite of the markedly increased rate of apoptosis of bthalassemic erythroid precursors in the bone marrow, the inspection of bone marrow aspirates of these patients does not show an increased number of dying erythroblats. This apparent paradox was explained by the recent demonstration that dying b-thalassemic erythroblasts are rapidly phagocytosed by macrophages, whose number and activation are enhanced. 151 The mechanisms involved in the recognition of apoptotic erythroblasts by macrophages are not fully understood, but they seem to involve at least the CD36 present on the membrane of macrophages and phosphatidylserine residues exposed on the membrane of apoptotic erythroblasts. 151 The mechanism of recognition and engulfment of apoptotic cells by macrophages is a complex phenomenon, which seems to involve several receptors on the membrane of activated macrophages, such as CD14 and CD36 152 and a receptor of recent identification, which does not correspond to any known membrane antigen of macrophages. 153 
Apoptotic mechanisms in megaloblastic anemias
Megaloblastic anemia is caused by the deficiency of folate or cobalamin (Vitamin B12). This type of anemia is characterized by pancytopenia resulting from the death of differentiating hemopoietic cells, and particularly of erythroid precursors, before they reach the terminal maturation. The demonstration that apoptosis plays an important role in the genesis of anemia observed in megaloblastic anemias was obtained in studies in animal models. An in vitro model of megaloblastic anemia was based on the culture of early erythroid precursors isolated from the spleens of mice that were fed with a folate-free diet during the acute erythroblastosis phase of disease induced by the Friend virus. 154 When these erythroblasts were grown in folate-rich medium they survived, proliferated and underwent terminal maturation. 154 Interestingly, the addition of thymidine to the folate-free medium inhibited the apoptosis, thus suggesting that folate deficiency leads to a defect in thymidine synthesis with consequent uracil misincorporation into DNA. This misincorporation of uracil into DNA may induce double-stranded breakage of DNA with consequent induction of an apoptotic process. This hypothesis was directly confirmed showing that erythroblasts undergoing apoptosis due to folate deficiency have increased uracil misincorporation into DNA and increased p53 levels. 155 More recent studies based on the same cellular model showed that megaloblastic erythroblasts first accumulate in the S-phase and then undergo apoptosis. 156 Finally, experiments in p53 À/À mice provided clear evidence that the induction of apoptosis in folatedeficient erythroblasts does not require p53. 156 
Apoptotic mechanisms underlying the defective erythropoiesis in myelodysplasias
Myelodysplasias are an example of a disease in which the development of pathologic apoptotic mechanisms is responsible for several features of the hematologic manifestations of this disease. Myelodysplastic syndromes comprise a heterogeneous group of disorders of hemopoietic stem cells characterized by a hypercellular bone marrow with several morphologic features of dysplasis, associated with peripheral blood cytopenias affecting red blood cells, granulocytes and platelets, and a variable incidence of transformation into acute myeloid leukemia (AML). The presence of anemia dominates the clinical picture. According to the probability of progressing to AML, myelodysplasias are divided into low and high risk: the low-risk myelodysplastic syndromes include refractory anemia and refractory anemia with ringed sideroblasts and have a low probability of progression and the high-risk patients exhibit severe cytopenia, increased percentage of blasts or cytogenetic abnormalities.
A hallmark of the disease consists in the presence of a hypercellular bone marrow, associated with peripheral blood cytopenia. It has been suggested that a high level of apoptosis is responsible for the ineffective erythropoiesis observed in myelodysplastic syndromes (MDS). 157 This increased rate of apoptosis is typical of the early and intermediate stages of development of the disease. An increased sensitivity to apoptosis is replaced by an increased resistance to apoptosis during progression of the disease to leukemia. 158 Increased apoptosis of bone marrow precursors is a feature typically observed in the majority of MDS patients. 159 The analysis of the mechanisms involved in the increased rate of apoptosis in MDS showed an involvement of both the extrinsic and intrinsic apoptotic pathways. A large number of studies provided evidence that the activation of the Fas/FasL system may represent an important pathogenetic mechanism in MDS. [160] [161] [162] These initial observations were carefully confirmed and extended in a recent study 163 where CD34 þ cells were isolated from the bone marrow of MDS patients and grown in a two-step liquid suspension culture system suitable for selective erythroid differentiation. Using this cell culture system, the authors showed that MDS CD34 þ cells grow normally during the initial proliferation/differentiation steps until they reach the stages of proerythroblasts, while their growth significantly declines as compared to controls due to an increased rate of apoptosis. 163 Interestingly, Fas antigen expression in MDS patients was more elevated than in controls during all stages of erythroid differentiation/maturation; furthermore, in mature erythroblasts, FasL expression was significantly higher in MDS than in controls. 163 According to these findings, it was concluded that MDS erythroid cells exhibit an exacerbation of the physiologic mechanisms of Fas-mediated control of erythropoiesis and exhibit a Fas-dependent apoptosis, even in the presence of high Epo levels. Interestingly, Fas-triggered apoptosis in bone marrow cells of MDS patients with refractory anemia with ringed sideroblasts is significantly improved by G-CSF treatment; particularly, the addition of G-CSF to CD34 þ cells improves erythroid colony formation in these patients. 164 As mentioned above, patients with more advanced stages of the MDS disease and with poor prognosis due to the presence of cytogenetic abnormalities may exhibit a condition different from that reported in MDS patients with refractory anemia (RA) or RA with ringed sideroblasts. In fact, some of these patients may exhibit an increased resistance to apoptosis instead of an increased sensitivity. 165 This issue was recently reinvestigated, providing clear evidence that the heterogeneity displayed by this group of MDS patients is due to the heterogeneity of the cytogenetic abnormalities: 166 in fact, these patients have three different types of cytogenetic abnormalities represented by trisomy 8, monosomy 7 and 5q À deletion. 166 There is also evidence that the TRAIL/TRAILRs system may play a role in the ineffective hemopoiesis observed in MDS. Both TRAIL and TRAILR1 and -R2 are expressed at increased levels in the bone marrow of MDS patients compared to the respective levels observed in normal controls. 166 Furthermore, hemopoietic procursors derived from the bone marrow of MDS patients are supranormally sensitive to TRAIL-mediated apoptosis. 167 There is evidence, however, that in MDS, in addition to the extrinsic apoptotic pathway the intrinsic apoptotic pathway is also activated. The hallmark of activation of the intrinsic apoptosis signalling pathway is the release of apoptogenic factors from mitochondria. In fact, markers of mitochondrial damage are commonly seen in MDS, including cytochrome c release, 168 accumulation of iron in the mitochondrial matrix of ringed sideroblasts 169 and the occurrence of mitochondrial DNA mutations. 170 Interestingly, in a recent study carried out on refractory anemia with ringed sideroblasts, it was shown that a significant proportion of erythroid progenitors display a spontaneous release of cytochrome c from mitochondria with consequent activation of caspase-9. 168 The addition of G-CSF significantly inhibited cytochrome c release and caspase activation.
According to these observations, it was suggested that the increased susceptibility to apoptosis in MDS cells is caused by events sensitizing these cells to death receptor triggering. Particularly, a current conceivable model to explain apoptosis in RA and RA with excess of ringed sideroblasts implies that increased sensitivity to triggering of death receptors is dependent on constitutive mitochondrial signalling, with consequent cytochrome c release and activation of caspase-9. 168 It is important to note that in MDS, apoptosis is markedly increased not only in the erythroid lineage but also in the myeloid, megakaryocytic, B-lymphoid and stromal cellular elements of the bone marrow. 171 
Apoptotic mechanisms in aplastic anemia
A large set of studies has suggested that the triggering of apoptotic mechanisms could play a relevant role in the pathogenesis of aplastic anemia.
Two main types of aplastic anemia are observed in children: the Diamond-Blackfan anemia and the Fanconi anemia. Diamond-Blackfan anemia (BDA) is characterized by a chronic aregenerative disease, starting during the neonatal period or infancy. The hallmark of this condition consists in a bone marrow exhibiting a selective marked decrease of erythroid precursors in the bone marrow. Initial studies have shown that both BFU-E and CFU-E derived from the bone marrow of Diamond-Blackfan patients are more sensitive to Epo deprivation than their normal counterparts; particularly, apoptotic changes, such as DNA fragmentation, were detected within 3 h after Epo deprivation, while they appeared after 9 h in controls. 172 In another study, a marked increase in serum concentration of FasL was observed in the majority of DBA patients. 173 Although this observation suggests that activation of cytotoxic lymphocytes occurs in DBA, the origin of increased serum FasL level is unclear. It may be suggested that certain subsets of cytotoxic lymphocytes overproduce FasL and through this mechanism exert an inhibitory effect on erythroid progenitors/precursors.
In 25% of cases, it was shown that DBA occurs due to the mutation of the gene encoding the ribosomal protein S19. 174 There is clear evidence that the mutation of this gene is responsible for the development of erythroblastopenia in DBA patients. 175 However, it remains largely unclear why the loss of this ribosomal protein, whose synthesis is observed particularly in immature erythroblasts and decreasing progressively during erythroid maturation, 176 induces the development of anemia and to the increased sensitivity to apoptosis observed in DBA patients.
Fanconi anemia (FA) is a rare autosomal recessive disease characterized by congenital abnormalities, progressive bone marrow failure and cancer susceptibility. The major clinical problems of this condition depend on the development of pancytopenia. One of the major features of the disease is related to the development of a progressive megaloblastic anemia. Recent studies have provided evidence that FA results from the mutation of one of the eight genes (FANC A, B, C, D1, D2, E, F and G). 177, 178 Many of these proteins form a nuclear complex that seems to be involved in the repair of double-strand DNA breaks. [177] [178] [179] Furthermore, one of these proteins, FANC C, plays a role in the modulation of apoptotic response to an oxidative stress. 177, 178 Several studies have provided evidence that FA hemopoietic progenitors exhibit an increased sensitivity to cell death induced by death receptor triggering. In this context, initial studies showed that bone marrow CD34 þ cells of FA patients exhibited an increased expression of Fas that correlated with increased sensitivity to anti-Fas antibody-mediated inhibition of colony formation. 180 These findings have been extended in other studies showing that both erythroid and granulo-monocytic progenitors are highly sensitive to the inhibitory effect exerted by IFN-g: particularly, very low doses of this cytokine inhibited colony formation in FA patients, but not in normal controls. 181 In line with these findings, HPCs from mice nullizygous for the FANC C locus are hypersensitive to the inhibitory effects induced by IFN-g. 181 The increased sensitivity of FA HPCs to IFN-g was related to the capacity of this cytokine to upregulate Fas.
In addition to IFN-g hypersensitivity, FA bone marrow cells exhibited a high rate of spontaneous apoptosis and hypersensitivity to FasL-mediated apoptosis. 182 Interestingly, the overexpression of the FA group C gene protects HPCs from death induced by Fas-mediated apoptosis. 183 Experiments performed on FAN C gene knockout mice provided further evidence that an increased sensitivity of erythroid progenitors to TNF-a and FasLmediated apoptosis could represent the main mechanism involved in the genesis of anemia in FA patients. 184 As it is largely expected, the apoptotic responses in FA hemopoietic cells to IFN-g, TNF-a and FasL are mediated via the caspase-8-dependent activation of caspase-3. 185 The inhibitory effects of IFN-g and TNF-a in FA on erythropoiesis and more generally on hematopoiesis are related not only to a marked activation of the death receptor apoptotic signalling but also to induction of the release of nitric oxide, which exerts an inhibitory effect on hematopoiesis. 186 In addition to pediatric aplastic anemia, there is evidence also in acquired aplastic anemia about the involvement of apoptotic mechanisms. The majority of acquired aplastic anemias are related to physiopathological mechanisms dependent upon a Tcell-mediated, organ-specific destruction of bone marrow hemopoietic cells. 187 Thus, there is evidence that a significant proportion of these patients exhibit an increased expression of Fas on CD34 þ cells and abnormal levels of increased apoptosis. 188 Increased FasL levels are observed in T lymphocytes of these patients 189 and these cells seem to be responsible for the destruction of hemopoietic progenitors in aplastic anemia.
Interestingly, the gene expression profile of CD34 þ cells of aplastic anemia patients (mostly adult patients) demonstrated an increased expression of a large number of genes implicated in apoptosis and cell death, compared to CD34 þ cells isolated from normal subjects. 190 This important observation indicates that in aplastic anemia, CD34 þ cells represent the main target of an immunologically mediated damage.
Apoptotic mechanisms in the genesis of erythrocytosis associated with various pathologic conditions
Recent studies suggest an implication of apoptotic mechanisms in the genesis of erythrocytosis associated with various types of pathologic conditions. Particularly, these studies have shown a possible involvement of the renin angiotensin system in the genesis of erythrocytosis observed following a kidney transplant 191 or in association with congestive heart failure, 192 chronic obstructive pulmonary disease, 193, 194 essential, malignant, or renovascular hypertension [195] [196] [197] or with chronic hemodialysis. 198, 199 The pathogenesis of erythrocytosis observed in these conditions is complex in that erythropoietin, angiotensin II and insulin-like growth factor I are all involved.
The role of the renin-angiotensin system is particularly relevant. In fact, angiotensin II stimulates the proliferation of normal erythroid progenitors, 200 while a lack of angiotensin-converting enzyme causes anemia. 201 The mechanism through which angiotensin II stimulates the proliferation of erythroid progenitors is unknown, but it seems to involve an enhanced survival of erythroid cells. This conclusion is strongly supported by studies carried out using inhibitors of the angiotensin-convertory enzyme: these inhibitors induce apoptosis of erythroid progenitors/precursors, 202 via induction of death receptor pathways. 203 It is of interest to note that these inhibitors have been successfully used in vivo for the treatment of these forms of erythrocytosis.
Concluding remarks
Growing evidences outlined in the present review indicate that apoptotic mechanisms play an important role in the control of erythropoiesis under physiologic and pathologic conditions.
Here, it is important to underline some general conclusions.
(1) Studies on the role of Fas/FasL system in erythropoiesis have provided evidences suggesting that mature erythroblasts may exert a negative control on the level and rate of maturation of immature erythroid cells acting through a ligand/receptor mechanism, with death ligands expressed on mature erythroid cells and the death receptor being present on the surface of immature erythroblasts. This mechanism may account for the low, but significant, level of ineffective erythropoiesis associated with premature death of erythroid cells observed in normal subjects. 204 Furthermore, this mechanism may represent an additional tool of control of erythropoiesis, in addition to the negative feedback mechanism of control of erythropoiesis based on modulation of erythropoietin production according to oxygen level.
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(2) There is evidence not only for the erythroid lineage but also for the granulocytic system that death ligands/receptors may exert an important physiologic homeostatic control. These findings are reminiscent of those observed in lymphocytes, where there is clear evidence of about the key role of death receptors/ligands in the homeostatic control of their number. 205, 206 The continuous death of a part of lymphocytes is an essential process needed to maintain a constant lymphocyte population in the face of a continuous flux on new lymphocytic elements. 205, 206 (3) Some apoptotic mechanisms are spontaneously activated and are required for the process of normal erythroid maturation. This is the case of a mild caspase activation occurring during late stages of erythroid maturation at the polychromatophilic stage and required for a normal process of erythroid maturation. This is a general phenomenon observed also during megakaryocytic maturation and monocyte to macrophage maturation. It is of interest to note that caspase activation is also required for the differentiation of other cell types, such as keratinocytes and corneal cells. represented by two transcription factors, Tal-1 and GATA-1, both essential for erythroid differentiation and survival. This finding is novel, in that it implies a new mechanism through which the activation of the apoptotic machinery may affect cell differentiation. Recently, it was shown that in myogenic cells, death receptor triggering leads to an inhibition of cell differentiation, a phenomenon that implies caspase activation, with consequent cleavage of the retinoblastoma protein (Rb) and the cyclin kinase inhibitor p21, both required for muscle differentiation and the activation of PW1, a protein involved in p53-dependent cell death and required for the translocation of Bax to mitochondria.
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(5) Immature erythroblasts are also sensitive to the apoptotic triggering mediated by activation of the intrinsic apoptotic pathway, as activated by chemiotherapic antitumor agents. This finding is potentially important, in that it may explain the mechanism through which chemiotherapeutics induces anemia. Interestingly, the apoptosis of immature erythroid cells induced by antitumor drugs is inhibited by SCF and this observation may pave the way to the development of therapies aimed at limiting or overcoming the problem of chemotherapy-induced anemia. (6) Apoptotic mechanisms are frequently activated in several pathologic conditions associated with the development of anemia. The considerable progress in our understanding of the apoptotic mechanisms underlying these conditions may pave the way towards improving the treatment of some of these diseases.
